RS Oncology's PRX3 Inhibitor (RSO-021) Shows Promise in Fight Against Deadly Mesothelioma, Rooted in Discovery Science from the University of Vermont

RS Oncology's PRX3 Inhibitor (RSO-021) Shows Promise in Fight Against Deadly Mesothelioma, Rooted in Discovery Science from the University of Vermont Phase 1 Clinical Trial Shows 67% Disease Control BOSTON — RS Oncology, LLC (“RSO” or the “Company”), a Boston-based clinical-stage biotechnology company, today highlighted results from a Phase 1 clinical trial of its lead candidate, RSO-021, published July 14 in Nature Communications. The study, led by Brian Cunniff, Associate Professor at the University of Vermont (UVM) and Chief Science Officer for RSO, together with an international team of collaborators, reports on a first-in-human trial of a novel therapeutic approach discovered at UVM and advanced into the clinic by RS Oncology.

The release as fetched from its publisher. rsoncology.com ↗